Disease · EFO_1001927

cutaneous squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cutaneous squamous cell carcinoma. Diseases, record EFO_1001927. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001927

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cutaneous squamous cell carcinoma
Open Targets ID: EFO_1001927
Highest stage of its drugs: Approval, for 1 of its 56 drugs, from TTD

Source Open Targets

Drugs56

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CEMIPLIMAB	CHEMBL4297723	Antibody	Approval	TTD	28	27	27	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2/3	ClinicalTrials.gov	20	19	19	Drugs and targets
INTISMERAN AUTOGENE	CHEMBL6068256	Oligonucleotide	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	8	8	8	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 56

See all 56 drugs

Targets67

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	8	Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	3	Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
LAG3	Lymphocyte activation gene 3 protein	3	Lymphocyte activation gene 3 protein inhibitor	Phase 2	https://conductscience.org/library/genes/3902	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 67

See all 67 targets

Trials88

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02760498	Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Phase 2	432	2024-12-11	Advanced Cutaneous Squamous Cell Carcinoma	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT03284424	Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)	Phase 2	159	2021-11-19	Squamous Cell Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02509507	Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611	Phase 1/2	127	2022-12-30	Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors	PEMBROLIZUMAB, TALIMOGENE LAHERPAREPVEC	Its record names the disease	ClinicalTrials.gov
NCT04154943	Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma	Phase 2	79	2023-02-08	Cutaneous Squamous Cell Carcinoma	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01198028	Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma	Phase 2	42	2020-06-11	Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma	ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00652080	An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)	Phase 1/2	35	2019-02-15	Squamous Cell Carcinoma	UBIDECARENONE	Its record names the disease	ClinicalTrials.gov
NCT03901573	High-Risk Skin Cancers With Atezolizumab Plus NT-I7	Phase 1/2	31	2025-10-22	Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma	ATEZOLIZUMAB, EFINEPTAKIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT04808999	Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)	Phase 2	30	2025-05-29	Squamous Cell Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04812535	Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.	Phase 2	30	2025-02-11	SCC - Squamous Cell Carcinoma of Skin	PEMBROLIZUMAB, VILOBELIMAB	Its record names the disease	ClinicalTrials.gov
NCT01979211	Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck	Phase 2	24	2022-05-10	Head and Neck Cancer	CETUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 88

See all 88 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course vs Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course: deaths from any cause	97 of 159	1 of 3	162	NCT03284424	Trial comparisons
Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course vs Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course: serious adverse events	87 of 159	2 of 3	162	NCT03284424	Trial comparisons
Recurrent or Metastatic Cutaneous cSCC Cohort vs Locally Advanced Unresectable cSCC Cohort: Number of Participants Who Experienced One or More Adverse Events (AEs)	102 of 105	51 of 54	159	NCT03284424	Trial comparisons
Recurrent or Metastatic Cutaneous cSCC Cohort vs Locally Advanced Unresectable cSCC Cohort: Number of Participants Who Discontinued Study Treatment Due to AE	20 of 105	11 of 54	159	NCT03284424	Trial comparisons
ITT Population vs PP Population: Percentage of Participants With a Complete Response	8 of 34	5 of 27	61	NCT00652080	Trial comparisons
Nivolumab, Tacrolimus, and Prednisone vs Ipilimumab, Nivolumab, Tacrolimus, and Prednisone: deaths from any cause	4 of 10	3 of 6	16	NCT03816332	Trial comparisons
Nivolumab, Tacrolimus, and Prednisone vs Ipilimumab, Nivolumab, Tacrolimus, and Prednisone: serious adverse events	6 of 10	6 of 6	16	NCT03816332	Trial comparisons
Dasatinib 100 mg vs Dasatinib 70 mg: serious adverse events	0 of 3	0 of 4	7	NCT00563290	Trial comparisons

Papers from its trials45

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40152791	RESULT	1	PubMed
32673170	RESULT	1	PubMed
23182701	RESULT	1	PubMed
42921711	DERIVED	1	PubMed
42558795	DERIVED	1	PubMed
42102329	DERIVED	1	PubMed
41137728	DERIVED	1	PubMed
41062829	DERIVED	1	PubMed
41022754	DERIVED	1	PubMed
40875250	DERIVED	1	PubMed

1 to 10 of 45

See all 45 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001927

GET https://conductscience.org/api/diseases/v1/EFO_1001927/drugs?page=2

API reference For AI assistants